HR: 1.37; 95% CI: 1.25-1.51; p<0.0001), and ACC/AHA type B2C lesions (HR: 1.47; 95% CI: 1.14-1.90; p¼0.003). The influence of these factors varied over time (Table 1) .
BACKGROUND The novel drug-filled coronary stent (DFS; Medtronic, Inc., Santa Rosa, CA) is formed from a continuous tri-layered wire with the innermost layer removed to create a hollow strut lumen that functions as an internal drug reservoir. Small holes (w20 mm) are laser drilled into the abluminal side of the stent, and the internal chamber is loaded with sirolimus. The DFS provides controlled drug elution from an internally loaded drug platform without utilization of a polymeric matrix, and thus may avoid chronic inflammation and adverse vascular responses associated with stents using polymer-based drug-release. A porcine coronary model demonstrated complete stent strut coverage at 28 days without inflammation. Clinical outcomes in humans with this device have not yet been assessed.
METHODS
The Clinical Evaluation of the Medtronic Polymer-Free Drug-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions: REVascularization using a non-polymeric drug ELUTing stent with Internal drug lOadiNg (RevElution Trial) is a first-in-human prospective, multicenter, non-randomized study of the DFS. Approximately 100 subjects will be enrolled at 15 international sites and followed through 5 years. Subjects with de novo lesions (single lesion or two lesions in separate target vessels) in native coronary arteries with a reference vessel between 2.25 and 3.50 mm in diameter will be treated with the DFS. Baseline optical coherence tomography (OCT) will be performed, and subjects will be assigned based on sequence of enrollment into cohorts with different durations of paired OCT follow-up at 1, 2, 3, and 6 months post implantation (15 subjects in each), as well as at 9 and 24 months (30 subjects in each). In addition to serial OCT imaging, other standard clinical and angiographic/IVUS parameters will also be assessed.
RESULTS AND CONCLUSIONS
The DFS is designed to provide controlled release of sirolimus through an internally loaded drug platform, thus eliminating the need for a polymeric matrix. RevElution is the first study to assess the vascular responses, efficacy, and safety of this novel device. One-month OCT outcomes from the RevElution study will be reported at TCT 2015, providing an early assessment of neointimal coverage and stent apposition after DFS implantation. BACKGROUND A novel drug-filled coronary stent (DFS; Medtronic, Inc., Santa Rosa, CA) provides controlled drug elution from an internally-loaded drug platform without using a polymeric matrix, and thus may avoid chronic inflammation and adverse vascular responses associated with a polymer. The stent is formed from a continuous trilayered wire with the innermost layer removed to function as a reservoir that elutes sirolimus from small holes (w20 mm) in the abluminal side of the stent. The impact of the reservoir and holes on mechanical properties of the stent and its radiopacity has not been previously reported.
METHODS Stent integrity and mechanical strength with the DFS were compared to the current generation Resolute Onyx TM drugeluting stent (DES, Medtronic, Inc.). Radial strength was tested by measuring the force required to radially compress the stent (diameter 3.0 mm) in a standard iris test. Longitudinal stent deformation was tested by measuring the peak force required to compress the stent by 1 cm after deployment in a 1.5 cm radius curved mock vessel (3.0 x 18 mm). Results are reported as average AE standard deviation. Radiopacity was tested under fluoroscopy in a porcine coronary artery model. CONCLUSIONS The DFS utilizes an internally loaded drug platform to provide controlled release of sirolimus without using a polymeric matrix. Mechanical strength, as well as radiopacity, are at least comparable to current-generation DES. These in-house tests are being independently validated and will be available for presentation at TCT 2015.
RESULTS

